Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation

European Journal of Pharmaceutical Sciences

Volumn 62, Issue , 2014, Pages 309-316

  Schwartz, Juana ^a   Moreno, Esther ^a   Fernández, Celia ^a   Navarro Blasco, Iñigo ^a   Nguewa, Paul A ^a   Palop, Juan A ^a   Irache, Juan M ^a   Sanmartín, Carmen ^a   Espuelas, Socorro ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

4 Bis aminophenyldiselenide; Chitosan hydrogel; Cutaneous leishmaniasis; Discovery algorithm; Topical treatment

Indexed keywords

ANTILEISHMANIAL AGENT; BIS 4 AMINOPHENYLDISELENIDE; CHITOSAN; ORGANOSELENIUM DERIVATIVE; PAROMOMYCIN; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; ANTIPROTOZOAL AGENT; BIS-4-AMINOPHENYLDISELENIDE; DRUG CARRIER; HYDROGEL;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CHITOSAN HYDROGEL; CONTROLLED STUDY; DIFFUSION; DISEASE COURSE; DOSE RESPONSE; DRUG PENETRATION; DRUG RETENTION; EX VIVO STUDY; FEMALE; FRANZ DIFFUSION; HYDROGEL; IN VIVO STUDY; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PARASITE LOAD; PERITONEUM MACROPHAGE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SKIN CULTURE; SKIN LEISHMANIASIS; SKIN PENETRATION; TOPICAL TREATMENT; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; LEISHMANIASIS, CUTANEOUS; METABOLISM; PARASITOLOGY; SKIN; SKIN ABSORPTION; SWINE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANILINE COMPOUNDS; ANIMALS; ANTIPROTOZOAL AGENTS; CHITOSAN; DRUG CARRIERS; FEMALE; HYDROGELS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACROPHAGES, PERITONEAL; MICE, INBRED BALB C; ORGANOSELENIUM COMPOUNDS; PARASITE LOAD; SKIN; SKIN ABSORPTION; SWINE;

EID: 84903935303     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.06.010     Document Type: Article

References (40)

1. F.K. Akomeah Topical dermatological drug delivery: quo vadis? Curr. Drug Deliv. 7 2010 283 296
2. N. Bavarsad, B.S. Fazly Bazzaz, A. Khamesipour, and M.R. Jaafari Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice Acta Trop. 124 2012 33 41
3. L.S. Bernardes, C.L. Zani, and I. Carvalho Trypanosomatidae diseases: from the current therapy to the efficacious role of trypanothione reductase in drug discovery Curr. Med. Chem. 20 2013 2673 2696
4. G. Carneiro, D.C. Santos, M.C. Oliveira, A.P. Fernandes, L.S. Ferreira, G.A. Ramaldes, E.A. Nunan, and L.A. Ferreira Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis J. Liposome Res. 20 2010 16 23
5. G. Carneiro, M.G. Aguiar, A.P. Fernandes, and L.A. Ferreira Drug delivery systems for the topical treatment of cutaneous leishmaniasis Expert Opin. Drug Deliv. 9 2012 1083 1097
6. G.A. Castro, D.S. Nascimento, A.P. Fernandes, E.A. Nunan, and L.A.M. Ferreira In vitro skin permeation of paromomycin from topical formulations across normal and stripped hairless mouse skin Stp. Pharma. Sci. 13 2003 203 208
7. T. Dai, M. Tanaka, Y.Y. Huang, and M.R. Hamblin Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects Expert Rev. Anti Infect. Ther. 9 2011 857 879
8. R. Don, and J.R. Ioset Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections Parasitology 2013 1 7
9. J. El-On, G.P. Jacobs, E. Witztum, and C.L. Greenblatt Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals Antimicrob. Agents Chemother. 26 1984 745 751
10. L.S. Ferreira, G.A. Ramaldes, E.A. Nunan, and L.A. Ferreira In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis Drug Dev. Ind. Pharm. 30 2004 289 296
11. M. Forster, M.A. Bolzinger, H. Fessi, and S. Briancon Topical delivery of cosmetics and drugs. Molecular aspects of percutaneous absorption and delivery Eur. J. Dermatol. 19 2009 309 323
12. M. Fukuda, Y. Morita, K. Sasaki, and Y. Yamamoto Studies on the binding mechanism of fluoroquinolones to melanin J. Infect. Chemother. 6 2000 72 76
13. T. Garnier, and S.L. Croft Topical treatment for cutaneous leishmaniasis Curr. Opin. Investig. Drugs 3 2002 538 544
14. T. Garnier, M.B. Brown, M.J. Lawrence, and S.L. Croft In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis J. Pharm. Pharmacol. 58 2006 1043 1054
15. T. Garnier, A. Mantyla, T. Jarvinen, J. Lawrence, M. Brown, and S. Croft In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs J. Antimicrob. Chemother. 60 2007 802 810
16. S. Gattu, and H.I. Maibach Enhanced absorption through damaged skin: an overview of the in vitro human model Skin Pharmacol. Physiol. 23 2010 171 176
17. J. Giaimis, Y. Lombard, M. Makaya-Kumba, P. Fonteneau, and P. Poindron A new and simple method for studying the binding and ingestion steps in the phagocytosis of yeasts J. Immunol. Methods 154 1992 185 193
18. G.S. Goncalves, A.P. Fernandes, R.C. Souza, J.E. Cardoso, F. de Oliveira-Silva, F.C. Maciel, A. Rabello, and L.A. Ferreira Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis Acta Trop. 93 2005 161 167
19. U. Gonzalez, M. Pinart, L. Reveiz, and J. Alvar Interventions for Old World cutaneous leishmaniasis Cochrane Database Syst. Rev. 2008 CD005067
20. U. Gonzalez, M. Pinart, M. Rengifo-Pardo, A. Macaya, J. Alvar, and J.A. Tweed Interventions for American cutaneous and mucocutaneous leishmaniasis Cochrane Database Syst. Rev. 2009 CD004834
21. M. Grogl, M. Hickman, W. Ellis, T. Hudson, J.S. Lazo, E.R. Sharlow, J. Johnson, J. Berman, and R.J. Sciotti Drug discovery algorithm for cutaneous leishmaniasis Am. J. Trop. Med. Hyg. 88 2013 216 221
22. M.R. Jaafari, N. Bavarsad, B.S. Bazzaz, A. Samiei, D. Soroush, S. Ghorbani, M.M. Heravi, and A. Khamesipour Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice Antimicrob. Agents Chemother. 53 2009 2259 2265
23. D.H. Kim, H.J. Chung, J. Bleys, and R.F. Ghohestani Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials PLoS Negl. Trop. Dis. 3 2009 e381
24. M.E. Lane Skin penetration enhancers Int. J. Pharm. 447 2013 12 21
25. M.E. Lane, J. Hadgraft, G. Oliveira, R. Vieira, D. Mohammed, and K. Hirata Rational formulation design Int. J. Cosmet. Sci. 34 2012 496 501
26. A. Mantyla, T. Garnier, J. Rautio, T. Nevalainen, J. Vepsalainen, A. Koskinen, S.L. Croft, and T. Jarvinen Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone J. Med. Chem. 47 2004 188 195
27. B. Monge-Maillo, and R. Lopez-Velez Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis Drugs 73 2013 1889 1920
28. OECD, 2004. Test No. 428: Skin Absorption. In Vitro Method. OECD Publishing.
29. G. Oliveira, J. Hadgraft, and M.E. Lane The role of vehicle interactions on permeation of an active through model membranes and human skin Int. J. Cosmet. Sci. 34 2012 536 545
30. D. Plano, Y. Baquedano, D. Moreno-Mateos, M. Font, A. Jimenez-Ruiz, J.A. Palop, and C. Sanmartin Selenocyanates and diselenides: a new class of potent antileishmanial agents Eur. J. Med. Chem. 46 2011 3315 3323
31. F. Poorrajab, S.K. Ardestani, A. Foroumadi, S. Emami, A. Kariminia, M. Behrouzi-Fardmoghadam, and A. Shafiee Selective leishmanicidal effect of 1,3,4-thiadiazole derivatives and possible mechanism of action against Leishmania species Exp. Parasitol. 121 2009 323 330
32. R.O. Potts, and R.H. Guy Predicting skin permeability Pharm. Res. 9 1992 663 669
33. I. Ramirez-Macias, C.R. Maldonado, C. Marin, F. Olmo, R. Gutierrez-Sanchez, M.J. Rosales, M. Quiros, J.M. Salas, and M. Sanchez-Moreno In vitro anti-leishmania evaluation of nickel complexes with a triazolopyrimidine derivative against Leishmania infantum and Leishmania braziliensis J. Inorg. Biochem. 112 2012 1 9
34. W.R. Ravis, A. Llanos-Cuentas, N. Sosa, M. Kreishman-Deitrick, K.M. Kopydlowski, C. Nielsen, K.S. Smith, P.L. Smith, J.H. Ransom, Y.J. Lin, and M. Grogl Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis Antimicrob. Agents Chemother. 57 2013 4809 4815
35. R. Reithinger, J.C. Dujardin, H. Louzir, C. Pirmez, B. Alexander, and S. Brooker Cutaneous leishmaniasis Lancet Infect. Dis. 7 2007 581 596
36. K. Seifert, P. Escobar, and S.L. Croft In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent J. Antimicrob. Chemother. 65 2010 508 511
37. A. Tiwari, S. Kumar, S.N. Suryawanshi, M. Mittal, P. Vishwakarma, and S. Gupta Chemotherapy of leishmaniasis part X: synthesis and bioevaluation of novel terpenyl heterocycles Bioorg. Med. Chem. Lett. 23 2013 248 251
38. WHO, 2010. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniasis, WHO technical report series 949, Geneva, 1-185.
39. J.W. Wiechers, A.C. Watkinson, S.E. Cross, and M.S. Roberts Predicting skin penetration of actives from complex cosmetic formulations: an evaluation of inter formulation and inter active effects during formulation optimization for transdermal delivery Int. J. Cosmet. Sci. 34 2012 525 535
40. X. Wu, B. Biatry, C. Cazeneuve, and R.H. Guy Drug delivery to the skin from sub-micron polymeric particle formulations: influence of particle size and polymer hydrophobicity Pharm. Res. 26 2009 1995 2001.